Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Adenocarcinoma 7Neoplasms 6Stomach Neoplasms 5Solid Tumors 2Pancreatic Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Esophageal Neoplasms 1CLDN18.2-positive Gastric Adenocarcinoma 1CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 12atezolizumab 11Gemcitabine 9pembrolizumab 8Injections 6Carboplatin 6Irinotecan 5Docetaxel 5Cetuximab 5tocilizumab 4navitoclax 4Leucovorin 4Fluorouracil 4Bevacizumab 4olaparib 3cobimetinib 3Oxaliplatin 3Nivolumab 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2tivozanib 2tislelizumab 2spartalizumab 2ridaforolimus 2plocabulin 2obinutuzumab 2motesanib diphosphate 2liposomal doxorubicin 2linifanib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors × zolbetuximab × Clear all
NCT01197885 2025-06-13

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 2 Completed
54 enrolled
Other solid neoplasm

Solid Tumors

NCT00909025 2024-11-21

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 1 Completed
15 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡